Table 2 Clinical characteristics
From: Cortico-cerebellar functional connectivity and sequencing of movements in schizophrenia
Group | Dg. SCH/SAF (%) | Duration | Episodes | Dose | AP MARTA/SDA(%) | BAS | AIMS | SAS | AntiPark (%) | NSS-T | SI | MC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SCH | 21/3 (87.5/12.5) | 9.2 (7.6) | 4.2(2.0) | 364.5 (203.1) | 13/11 (54.2/45.8) | 0.7 (1.9) | 0 | 1.2 (1.3) | 3 (12.5) | 4.0 (2.4) | 0.9 (1.4) | 0.2 (0.5) |
SQ+ | 5/2 (71.4/28.6) | 13.8 (7.2) | 5.7(1.3)* | 360.6 (195.8) | 4/3(57.1/42.9) | 0.6 (1.1) | 0 | 1.7 (1.5) | 1 (14.3) | 5.9* (2.2) | 0.3 (0.8) | 0.4 (0.8) |
SQ- | 16/1 (94.1/5.9) | 7.8 (7.4) | 3.6(1.9) | 366.1 (212.0) | 9/8 (52.9/47.1) | 0.7 (2.2) | 0 | 1.0 (1.1) | 2 (11.8) | 3.2 (2.1) | 1.1 (1.5) | 0.06 (0.2) |